Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/α-interferon

Medical Oncology

Volumn 15, Issue 3, 1998, Pages 191-198

  Alpaugh, R Katherine ^a   Von Mehren, Margaret ^a   Palazzo, Irma ^b   Atkins, Michael B ^c   Sparano, Joseph A ^d   Schuchter, Lynn ^e   Weiner, Louis M ^a   Dutcher, Janice P ^d  

^a FOX CHASE CANCER CENTER   (United States)

^b Jeanes Hospital   (United States)

^c TUFTS UNIVERSITY   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

IL 2; Melanoma; Monoclonal antibody; R24; IFN

Indexed keywords

ADRENALIN; ALKALINE PHOSPHATASE; CD8 ANTIGEN; DEXAMETHASONE; DIPHENHYDRAMINE; GANGLIOSIDE GD3; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY R24; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANAPHYLAXIS; ANOREXIA; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; URTICARIA; VOMITING;

EID: 0031794227     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02821938     Document Type: Article

References (23)

1. D3 ganglioside: A Phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 1985; 82: 1242.
2. D3 ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites. J Clin Oncol 1988; 6: 1636.
3. D3 monoclonal antibody in combination with Interferon-α in patients with malignant melanoma. J Biol Res Modifiers 1990; 9: 319.
4. Bajorin DF et al. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 1990; 50: 7490.
5. Casper ES et al. Biological study of R24 mouse monoclonal antibody in patients undergoing thoracotomy for pulmonary metastases from soft tissue sarcoma. Cancer Invest 1994; 12: 20.
6. Minasian LM et al. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-α and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood 1994; 83: 56.
7. Bukowski RM et al. Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patient with metastatic melanoma: Clinical and biological effects. J Immunother 1994; 15: 273.
8. Chachoua A et al. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma. J Immunother 1994; 16: 132.
9. Minasian LM et al. A Phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer 1995; 75: 2251.
10. Real FX et al. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: Specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res 1985; 45: 4401.
11. Hersey P et al. Potentiation of lymphocyte responses by monoclonal antibodies to the ganglioside GD3. Cancer Res 1986; 46: 6083.
12. D3 ganglioside. J Immunol 1987; 139: 1763.
13. + natural killer cells. Eur J Immunol 1994; 24: 1208.
14. Norihisa Y et al. Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T lymphocytes through a surface ganglioside (GD3). J Immunol 1994; 152: 485.
15. Boussiotis VA et al. R24 anti-GD3 ganglioside antibody can induce co-stimulation and prevent the induction of alloantigen-specific T cell clonal anergy. Eur J Immunol 1996; 26: 2149.
16. Goedegebuure PS et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study. J Clin Oncol 1995; 13: 1939.
17. Kawakami Y et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154: 3961.
18. Weiner LM et al. Phase I evaluation of combination therapy with interleukin-2 and γ-interferon. Cancer Res 1991; 51: 3910.
19. Creagen ET et al. Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive Phase II investigations. J Invest Dermatol 1990; 95: 1885.
20. Parkinson DR et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a Phase II study. J Clin Oncol 1990; 8: 1650.
21. Leagha SS. Interferons in the treatment of malignant melanoma. A review of recent trials. Cancer 1986; 57: 1675.
22. Weiner LM et al. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J Immunol 1993; 151: 2877.
23. Valone FH et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpress the proto-oncogene HER-2/neu. J Clin Oncol 1995; 13: 2281.